TY - JOUR T1 - Point-of-care digital cytology with artificial intelligence for cervical cancer screening at a peripheral clinic in Kenya JF - medRxiv DO - 10.1101/2020.08.12.20172346 SP - 2020.08.12.20172346 AU - Oscar Holmström AU - Nina Linder AU - Harrison Kaingu AU - Ngali Mbuuko AU - Jumaa Mbete AU - Felix Kinyua AU - Sara Törnquist AU - Martin Muinde AU - Leena Krogerus AU - Mikael Lundin AU - Vinod Diwan AU - Johan Lundin Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/19/2020.08.12.20172346.abstract N2 - Cervical cancer is highly preventable but remains a common and deadly cancer in areas without screening programmes. Pap smear analysis is the most commonly used screening method but is labour-intensive, subjective and requires access to medical experts. We developed a diagnostic system in which microscopy samples are digitized at the point-of-care (POC) and analysed by a cloud-based deep-learning system (DLS) and evaluated the system for the detection of cervical cell atypia in Pap smears at a peripheral clinic in Kenya. A total of 740 conventional Pap smears were collected, digitized with a portable slide scanner and uploaded over mobile networks to a cloud server for training and validation of the system. In total, 16,133 manually-annotated image regions where used for training of the DLS. The DLS achieved a high average sensitivity (97.85%; 95% confidence interval (CI) 83.95—99.75%) and area under the curve (AUCs) (0.95) for the detection of cervical-cellular atypia, compared to the pathologist assessment of digital and physical slides. Specificity was higher for high-grade atypia (95.9%; 95% CI 94.9—97.6%) than for low-grade atypia (84.2%; 95% CI 79.9—87.9%). Negative predictive values were high (99.3-100%), and no samples classified as high grade by manual sample analysis had false-negative assessments by the DLS. The study shows that advanced digital microscopy diagnostics supported by machine learning algorithms is implementable in rural, resource-constrained areas, and can achieve a diagnostic accuracy close to the level of highly trained experts.What is already known?• Cervical cancer can be prevented with Pap smear screening, but manual sample analysis is labor-intensive, subjective and not widely-available in regions with the highest disease prevalence• Novel digital methods, such as image-based artificial intelligence (AI), show promise for facilitated analysis of microscopy samples• Digital methods are typically limited to high-end laboratories, due to the requirements for advanced equipment and supportive digital infrastructureWhat are the new findings?• A point-of-care diagnostic system where samples are digitized with a portable slide scanner and analyzed using a cloud-based AI model can be implemented in rural settings and utilized to automatically interpret Pap smears and identify potentially precancerous samples with similar accuracy as a pathologist specialized in reading Pap smears.What do the new findings imply?• The results demonstrate how advanced digital methods, such as AI-based digital microscopy, can be implemented in rural, resource-limited areas, and used for analysis of microscopy samples, such as Pap smears.• This technology shows promise as a novel method for digital microscopy diagnostics, which can be implemented in rural settings, and could be of particular value in areas lacking cytotechnicians and pathologists.Competing Interest StatementJohan Lundin and Mikael Lundin are founders and co-owners of Aiforia Technologies Oy, Helsinki, Finland. The rest of the authors declare that there are no competing interests.Funding StatementThe Erling-Persson Family Foundation funded this study. In addition, this work has been supported by the Swedish Research Council, Sigrid Juselius Foundation, Finska Lakaresallskapet and Medicinska Understodsforeningen Liv och Halsa rf. Work for this project has also received funding from K. Albin Johanssons stiftelse, Stiftelsen Dorothea Olivia, Karl Walter och Jarl Walter Perklens minne, Wilhelm och Elsa Stockmanns stiftelse and Biomedicum Foundation. We thank the FIMM Digital Microscopy and Molecular Pathology Unit supported by Helsinki University and Biocenter Finland for outstanding assistance.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for the current study was issued by the Ethical Review Committee at the National Commission for Science, Technology and Innovation (Pwani University, Nacosti, Kenya) (No. ERC/PU-STAFF/005/2018). The study was also approved by the Helsinki Biobank (No. 359/2017).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe software used to develop the deep learning-algorithm in this study is commercially available at: https://www.aiforia.com/aiforia-create/, and the parameters and configurations required for replications of results are described in the manuscript. We aim to make the final algorithm publicly available for analysis of digital samples three (3) months following publication of the article. The model will be made available as an application program interface (API). Further requests for sharing of de-identified data (digitized samples) will be considered from researchers abiding the following principles: data will be securely stored with appropriate documentation and not disposed into publicly accessible domains or otherwise shared without explicit permission from the authors, data is only used with the aim to generate data for the public good. Applications are subjected to review by the Data Access Committee at Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland; e-mail: fimm-dac@helsinki.fi) ER -